-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EnC/w3Az0alDLFhrOIPcZdMCMwWeu/ZTcMXs+HPqqBZoIrCm97F/syY3c5bv0iNu
 TichgLrWYNVflxgqLFthnQ==

<SEC-DOCUMENT>0001193125-09-029210.txt : 20090213
<SEC-HEADER>0001193125-09-029210.hdr.sgml : 20090213
<ACCEPTANCE-DATETIME>20090213160020
ACCESSION NUMBER:		0001193125-09-029210
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090213
FILED AS OF DATE:		20090213
DATE AS OF CHANGE:		20090213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			3SBio Inc.
		CENTRAL INDEX KEY:			0001383790
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33295
		FILM NUMBER:		09603284

	BUSINESS ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
		BUSINESS PHONE:		86-24-2581-1820

	MAIL ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 6-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>REPORT OF FOREIGN ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>For the month of January 2009 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Commission File Number: 000-33295
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>3SBIO INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Translation of
registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>No.&nbsp;3 A1, Road 10 </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Shenyang Economy&nbsp;&amp; Technology Development Zone </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Shenyang 110027 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>People&#146;s Republic of China </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&nbsp;<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Yes&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-&nbsp;<U>N/A</U> </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3SBIO INC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">FORM 6-K </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3SBio Inc. is furnishing under the cover of Form 6-K: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibit&nbsp;99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><U>Press release, dated January&nbsp;20, 2009, regarding 3SBio Inc. Filing for SFDA Approval for TPIAO Label Extension for the Treatment of ITP.</U></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">SIGNATURE </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">3SBIO INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Dr. Jing Lou</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Dr. Jing Lou</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: February&nbsp;13, 2008 </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibit&nbsp;99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><U>Press release, dated January 20, 2009, regarding 3SBio Inc. Filing for SFDA Approval for TPIAO Label Extension for the Treatment of ITP.</U></FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g61703txpg3-4.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Contacts:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Investor Contact:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Investor Relations (US):</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">David Chen, COO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Mahmoud Siddig</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3SBio Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Taylor Rafferty</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">+86 24 2581 1820</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">+1 (212) 889-4350</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Investor Relations (HK):</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Media Contact:</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Ruby Yim</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Jason Marshall</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Taylor Rafferty</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Taylor Rafferty</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">+852 3196 3712</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">+1 (212) 889-4350</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>3SBIO INC. FILES FOR SFDA APPROVAL FOR TPIAO LABEL EXTENSION FOR </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE TREATMENT OF ITP </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>SHENYANG, PRC</B> &#151;
January&nbsp;20, 2009 &#151; 3SBio Inc. (NASDAQ: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December&nbsp;30,
2008 with the Chinese State Food and Drug Administration (SFDA) for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) in China. If the extension is approved, 3SBio expects that TPIAO for ITP will be
the only treatment of this kind available in China. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Launched in 2006, TPIAO is a recombinant human thrombopoietin product approved in China for the
treatment of chemotherapy induced thrombocytopenia, or platelet deficiency. The aim of this filing is to extend the label of TPIAO for use in the treatment of ITP. ITP is characterized by an immune system malfunction that perceives the body&#146;s
platelets as foreign and destroys them, potentially resulting in dangerously low platelet counts. There are today approximately eighty thousand patients diagnosed with ITP in China, with more than half of these patients resistant to conventional
steroid treatment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">TPIAO represents a new approach for the treatment of ITP, by stimulating the TPO receptor, which is intended to have the effect of
directly increasing platelet production to outpace platelet destruction by the immune system. The registration trial examined the safety and efficacy of a 14-day subcutaneous injection of TPIAO on ITP patients who are resistant to steroid treatment,
followed by a 14-day observation period. The results showed an overall patient response rate to TPIAO treatment of 60.27%, significantly higher than the Danazol control group response rate of 36.51%. Patients administered TPIAO also reached
effective platelet counts in 7 days, compared to 10 days for patients within the control group. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Jing Lou, Chief Executive Officer of 3SBio,
commented, &#147;The filing of TPIAO for ITP successfully caps our development initiatives for 2008 and we now have three new product candidates in the approval pipeline. As with NuLeusin and high dosage EPIAO, TPIAO for </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g61703txpg3-4.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">ITP represents a logical extension of an existing product franchise, in-line with our therapeutic focus and growth strategy. The successful completion of our
three Phase III trials demonstrates the strength of our research and development platform and highlights our operational excellence. Upon approval, TPIAO for ITP would provide a new treatment option for patients and will further enhance our
footprint within China&#146;s growing pharmaceutical market.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About the Phase III Study </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The Phase III study that 3SBio conducted was a multi-center, randomized, placebo-controlled study in ITP patients
who failed to respond to glucocorticoid treatment. All patients were administered Danazol, a synthetic steroid hormone drug routinely used to treat ITP. The treatment group was administered an additional 1.0 microgram/kg TPIAO subcutaneously daily
for 14 days. The primary endpoint of the trial was the measurement of effective platelet counts, in which maximum counts reached <U>&gt;</U>50x10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>9</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">/L
or increased <U>&gt;</U>30x10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>9</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">/L over the baseline, during the 14-day treatment. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The results of the Phase III study demonstrated TPIAO to be an effective treatment for ITP with tolerable mild
adverse effects. The overall response rate in the treatment group and the control group was 60.27% and 36.51%, respectively (p=0.0104). The platelet response time, characterized by the time required for platelet counts to reach
<U>&gt;</U>50x10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>9</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">/L or increase <U>&gt;</U>30x10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>9</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2">/L over the baseline, for the first 25% of patients in the TPIAO treatment and control group was 7 and 10 days, respectively. A 14-day TPIAO treatment was subsequently applied to patients in the control group whose platelet counts remained
<U>&lt;</U> 20x10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>9</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">/L. The overall response rate to the TPIAO treatment was 67%. The overall adverse events rate in the treatment and control group
was 34.25% and 26.15%, respectively; the rate of TPIAO-related adverse events for the two groups, including mild sleepiness, mild dizziness, fatigue, mild allergic reaction, and paroxysmal visual field defect, was 15.07% and 4.08%, respectively.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About 3SBio Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">3SBio Inc. is a leading, fully
integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at: www.3sbio.com. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements in this release may contain
&#147;forward-looking&#148; statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation
Reform Act of 1995. These statements are based upon 3SBio management&#146;s current expectations, and actual results could differ materially. Among the factors that could cause 3SBio&#146;s actual results to differ from what the company currently
anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products;
the completion of 3SBio&#146;s ongoing clinical trials as planned; </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g61703txpg3-4.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">receipt and timing of regulatory approvals for 3SBio&#146;s new products and uses; 3SBio&#146;s ability to expand its production, sales and distribution
network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in
the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio&#146;s financial results, please refer to the
company&#146;s filings with the Securities and Exchange Commission at www.sec.gov. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the
date of this press release. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g61703txpg3-4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g61703txpg3-4.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`)D%D;V)E`&3``````0,`%00#!@H-```4"P``(DT``"DA```Q
M^O_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\(`$0@`.P"J`P$1``(1`0,1`?_$`1$```("`04!```````````````)!P@&
M`0($!0H#`0$``00#`````````````````0(#!P@$!080```%!`$"!`0$!P``
M``````,$!08'``$""!$0($`Q$A0P01,5-"4U-R$B,D(C-A@1``("`0($`P0$
M!PL-``````(#`00%$1(`(1,&,4$442)"%6%Q(P<0,E(S)'46($"!<H)#@S2T
MM1?18I*BL]-$9(1%E39V$@`!`P$#!PD$"`<````````!``(#$2$2!"!`,4$B
M,A0P46%QD:%"$S.!L<&#\-'A8I(T!17Q@J(C0Z,D$P$``@(!`P,#!0$!````
M```!`!$A,4%187$0@9$@\*$P0+'!T?'A_]H`#`,!``(1`Q$```%_A5;V7A,^
MZCMIHZ+TF^J0```````````*3Y$Q>IK.^OOH!U2V]SS@]KH5G502,%4]0+M7
M)I19-11%7FA>2+?#JL=K1?\`I5(`&RF*39$QLKS.F!>XX')?9J]MGP;/(\]J
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MXM17W'2*(SU@.[V,LB7IQGE;DWZM9```&AMF=T1J````?__:``@!`0`!!0*I
M=75)M-5CO1,>R-X2?/V_93Q4F4M-UP)KG2NCXEUB1[DA[/18LFP1@C`2HJIR
M*15MK8Q3S#-GF.'N<<3@2VLB_P#544TC;)1,LF`1PC`0YXL6$Y[>:>LD,S%;
M?[&.,E4C603;$5R"@44R:VHXHZ-!#")S$ZYB@!D9LS4MU'%9I[3.A16WLV(`
MC)OI*SJPP#RS/]N(>UICID/!G2CKLQ#36U'>)\^GS\8='W%J&%8RVZYZS"_1
M6:AXXF#IAOQYD/'KQ:BBS%N%)`'0E<0,,<)';S491"9MAVIDVM:H\462SMH(
MK5CQR-=K,B)1LO%LO`EL#^SVMDEL5EM"6-BVH*W-:8Q4V,W]F)+>;%4R*ECD
MANC8M^O)P'<]LV@7A2>BTE9\U.R@*;?^O+:)'CU2^VB:^R\!+A9(IS)01U1+
M(K::X]36083=;I/<(;DO;FGE`L:O,1^1R]8!7G>]\)"UGU[B!C2$U5;5>,S9
M6.GX\XEDS<;]=GI?,(D&ZK-4DE1YQ4QE,(PG3[F4K8!%%)/"%'X2::L$,$.'
M-$@IB6@D"!A4/RNHN%EQ/KY*9B0VRL+"<@ID%A&'A/`\C,@JY^:VV>J7='Q;
M9ILZE:A_Z&..`6`>*F#+.P&XWZ[.+:,N*#=5'B15&/ZK5)YS&7)W]B5I\LTB
M]D)SM)=:1TNJ*A4(((<X8B"*!V^(9+`&RSBU;6DM8'UXFEWB1I%K<C!(EG7!
M/D):!@&>"`+#U934=4DIIF7HQ$C7V>4``;7><''440>W(NM/<,.&4CZ>1Q*I
M;MUA'#6S,1[(N(&)H0;L78<5\G?Q]C._8?<15[;ZUO!?_]H`"`$"``$%`J0B
MH)XZI)XR:8\_"-;^"LI)H:B6-%128_Q,<1,^[FD]'4LBR0IA*A9:2`U,(0/,
M+/X;6Q(W`.8A!G.Q!3/?FO\`"7",JOYJEJ&"D6<R38P%\.UK=S5!P#3G>=%"
MPI".BDS^6&(E&,;8#6OSX!J&<,B#H2A#@7\V-VZE#&30QBQ8(7+Z@O@$Y0$3
M#1)3*G\<BQ?//.X86+A7_>>"^9#\0![CT+GJ]-OZ/`__V@`(`0,``04"IPFA
M2))+405,MX1V6_*4Q3%33)0X$>+]>.ML;WJ]N.G%<5\\A,,+W[E-83;#JR7F
MF#H2R(EF`Q,1<*YKSKBN*YO:KWYJWG>N:SIUW4/KD,QLR78X53[<5X%'&*I/
MK25-,%2S#96<RYCI:KUS7'-<<5;SO5K5E?O=@V0JHSR00V7E3A(A&T["^>&9
M3.XA>K5?IS7//2_2]6\^MNCP*9AGFLJAD1;9XWQ<JR"`5+!9F1P<?0%?MQK^
M[+I:K=RJGA*98\FFT_/`V9M@'@,,(W6][2_=SQTYMUY[K>2A^',^W]:)Z/5X
M+__:``@!`@(&/P)<--N%CNVQ&";<U%5S05W2PHP2^IX7(X>:QS>4Z$ZX*W=.
M6?U/#[+V6M^\%_=LQ#=YNNJO14XEN@_`HQR"CVGDZ*4X@M$YLH>9/CPYK$#D
MUD_+,TJ\^R-H[$[&X(7;?Q=:\Z*G2.E<=$*2M%O2.4_CE>9XGN3,)%H?:58F
M!IV)#0A>6_=*>T:`X^_,3A_\K'>]-G@VI(]2NO!#D,3(*0,-?J3II/"*E.?S
MN)[<Q$\>O2A)"X7Z:.97W,87=+?L5YUV.,>Q<'A?0K:>?,[/.^7O*S]QI\CX
MIU_C/F7;O]"V>[[<R__:``@!`P(&/P)#%0[XD;V6H3Q;^L9J>>^/BO/C]/6.
MA-Q$&X>[E*(!QI>T98_3,3M,?8[[I6S0X8C9=J*`?7A':0A(RUA')]*B&&#O
M*;;9SJ-^*]:EN3=C/_1)H5T6S./:A@L<;QI^'J1AEW=2X*<U@?8.@Y5F5K[E
M9DW?!&$_%RBKFZ%5/)&W&*@IKV[P*8XZ;@]V8C$#TWA'#361OUJL9!:G82(U
MG?W)L3/$:)K#J:!W9CP[]\:$63M-`=[4>I7&R/IUJZT%\I7&XK\QJ'-F=OD_
M,T=RVOVW_?\`!-N<#_)?O>R^K?IV9E__V@`(`0$!!C\"X7FL2_H7*><Q11KS
M6Y<L9#*[A^)+QG0HX7DZ,]*P&B<C1*8EM&WIJ2R_*6?B!?$/[U?^M\7_`+0^
M%97'S)KG1>0I26B;]3=[ZCCP%@>*R^$OHUXJ9C%/AU2T/U,0V/SE9X>(/27*
M8_"-?N+,B&0,(8&)HJ*]DY7/@PJR?S`%Y2R0B>`INNY3"2T^FNQFL=T*<E,Z
M#OLUW6@1K[3VQ'"WH:MR7`+%.48L4U9Q!`Q;`F0,#&=8F.7%C)Y6[6Q^/J!+
M+-RVX$(2$>9F<Q'U1XSY<37I#GLT(G(E9HX\$UIT^)1W[%5C8_D\)QF-RS*&
M5L3LKX[-5YQ[[+-->E69),JV&3Y"+-T^SC(]P9NQZ7%XM$V+;H6;2$-PA$`M
M<2;#,RB(B/&9X_.]Q?\`@S_W_`5?GK\4QI;%EFL?9HUR*9TB)M:-KJ_ED/"W
MH:IR'+%JG),6*:LXW`Q;`F0,"&>4QRGBJJP]267737J@PH&;#X63>DO7\8^F
M$SI]'[N.Q<V@;^.O@=7.W=T36Q+FQ'I0+2)F6@4ZF0\T<IXA$D5O#WMS\/E!
MTE5E$^]"3(?<BTD9YQ\4>]'+B#+J/P=X@'*TAF9TB/=&]6&>46D1Y?&/+V<5
M\A0>NU3N*!]:PHMRVJ.-8F)]OMCRGC+98AWCC,;>R$A^5%.LRQM_E=/CNGNO
MO@G96O3<BW:JDYBQR.4RIN:`6&+D3])30GDL9B/"/#C,YGM7"5\#FL%CWY)4
M8[J!5OUZ:Y=9JVZQ&2BW5P+:<1!07T<9GMJXTG1VS=KEC9.9(E8[*+:R*L3.
MNBJ]E![8\H+3C#_=[6?*L=CU8U[DZZ*LYC,M@:[;$:Z&%*L0[=?"3+Z^*]*Q
MVSCL[=Z`#>RF85ZVS;?MCK,&&S*ZRY/\45P,#'%/+8BUENVEHM5[3\9C6@RF
MTD.%T>FFU#+-"2D?$#Y>41QWK'LQU6/.?#(TOIUXS-_N?MK&YF[7[B=539N`
MPV+K#0I,A(R+!]R#.9_AXS&2[6PZNWLYB\?9R%6:#'14N>C2;RJ6ZK6,5(O`
M)B"':4%QW!V=;:U]7#C4RN'ELR?I:ETR3:I@1:Z)%XP8#X#NG3CMQ&/1=^4H
M_3Z]C'H<QGSM;3`=S$"1+8E,QTX\]T^/&%L9U71R[<=6/(+D=A19D/>WA\#"
M\2CRG]RNOC3B,WF>HBH?*9J5PB/4W8&?$P@M`\MTZ^7`@(NN6K;X$1C5UFS8
M>>G+Q)C6G//BOVEW?8/)L-74B9VR>',XUKIHV)CJ;J&ND3/TQ^+Q8PV0'=L^
MUIW(&83?J%/V=A>O+='XIC\)\5^V+[I/"YA_2K=0N6.R+?S<JDN0HME[IQ^5
MI/MX8EP"U30)35L&"!BSC:8&,\B$AG28\^+@X7%XKMS'23,A?FHE-&MJ`?:6
M;)^Z,0M<>,SH(\9;M;LN[\_RV:J.QK<A3`OEE"O:B4V9%YP/K+1J*1`5Q(\^
M9<6LAF4'5R_=%E-XZ30D'TL?65*L>AXEI(/9!DPA^'=$<)^\7`5[%SIU$T^X
M:E0#9;0%/=-/*I%7VDJ6N=C=.8;1+V\5<-]X5*Q="N`(7W+C(!E@E+B!&<I0
MF1ZK1CQ:J=Q>8:\1?[;S5'+U^6_TK8EU>9^"U6+2Q6/Z#&..]OU=6_O*GQF<
M?W1W'2P]VQW$VVFO9&S)LK%0I+%T=%#1VR:YC^#C(]N=B6V]QYW/568Q5BE6
ML15I+O1-=S()RULM6Y4<BM:QGWYC7C(9KN"J=+-]R35VT&CML8_%4X/TZ[(\
M]EFPULF8_#&V/'CM&KVKEYQ2K5:_D;FRO7<5ME6PA:4NFPIOZ-M.=1C3=KX\
M4LK?8FN)XFODKC9GIH0)5`LV&21<@4OG/T1PSMK[H,0?1WM!%X*(Y'+9!2YV
MS=%3HFEC*4^(DR)G3QF/#CY]:LV\I6&.M:J!\ESG17$;RZV/K)BPL('QZ7AP
MS`YNHC$=U5J\V`6@I]%EZZOS[J0M(FIL5_%B9DM(YQ.FNG%NJ13*L9CZ%5`S
MX#U5^K;,?QS=QENX[2Q<[%$BGCQ.-80^PLFOLC'AU(5H`SY:S^#*O:H?6X:L
MW)X^Q\:C0.]RMWCT["8D9CPUTGRXAJYVFN0:LX\1-<PP)CZ8*.,5>+\>YCJ5
MD_X[ZRV%_K%Q?Q&21%G'Y*H^C<KS)##:UA<K:&X)$QW"7C$\6/V6O9K#Y<0,
MZ)6KTY"@3AB94FPIRX<*RGEO$]P^//BS]V'=EI]WIA?##NNL)]NA>Q1%%S%E
M9.9-]4E+*5ZS,C(:>$\<^'VK6%^4Y1VXBRF"/Y=8-D^#')`2IV"U\=ZYF?;Q
MC^Y,!FFGCG695C<[5B4'U8B3^5YNEJ:3ARXGQW*;&NFDQQGNYND*+5G%*KY*
MN&NQ.2IY:HBV*]>?2(QWC_FE'&7RO<]"W:NU,\VBEB,C;J#%8*5-PC((8`D7
M4:7.>?!CBISF#O0,^GNU\H^V*F_`;*]OJ"8Q/LD)^GB/NP[QRCLM@VY-&*$K
M;6V/1'?V_*<IC7ODGJI6>J&])3MC=.G..?97ZFRW]KK<8VO582F]P5^W<(9C
M.D^D;2&U<#7V-15D)^B>([BZ`?,^Y[UMK;.V.I&/HV&4Z=42TU%4&DSTCE,E
M^"IG\`$45M=B.Z5I1$`N#L6#KY=(C$0,*MREFH^'VG'XW_;OFOC_`,)^5PG,
M;)]-F\>G:>G+U6/CT[E:_E=+9/%O&9AL5\7F_3Z6R_-4[Z-P*)\_`EX'MDO`
M9TUX%R&`U;!@@:LQ-9C/@0&,R)1/%_MBC979S673-5ZT'!_+Z9S]NRR0ZPMK
M0]P!\>>O%+&5`EEF_:132$1KJQYPN/\`1W:_P<96YVD<+R>%QV.2-GI"XZM)
M1UZURXE1P0$U-?4HUB8CQ\N'U,]<2_NK!NZ5V=JTNOT&:34R4UPVCK/-;)"-
MN\?+7BYF,M:52QU!!V+5EY"``M<27Q3&XR\!B.93RX9W)7284T6^X^Y;.D3$
M5Z]WU2*BF?")-9<&-/;$^SC]CK7<F-K=Q]-;/EUAO1+[4=ZU==D#6]083K"]
M^^8\OP8GL>M858R99)69RBUF)3CZM-+AK!8TF>FZTUVL#X[!F?/C*U;JR3<R
M..^>.08[35\TS%-]<"B=-"]+LUX[@_\`JW_W9CO\O#;%EJZZ$A+'.>8J4I8\
MR-C#D0`(CV\4H[:UL4W9G!XRK;2/)U/"$#KN4B=/ZOM!A"4_!$>WCLO]39?^
MUUN*;*2I=:P%+`9^%C&IE7J415=VQXSLJ6"+ZAX+M,K`1E^W+=HQJR<;W8J^
MZ;2+21UU-8/<8%^3.GMXUGE&FLSY1$><SQ4PW;Y>MIA9QG;:;*??45?'M98S
M-P"CW9K()C?>\-!^GC\2/ZE\O_Z7\CZN'8BU/1<,^HQ]R!U.E<`9@&1'FLH]
MTQ\QG@J6;HLK^\4(LP,G1N!$S$'6LZ;3B8\IT*/..)16R>0K(+Q0FY:4F?Z-
M;(#@4H4ZS:L'H"D@Q[W,+V`$$QA3P'<_<B87EY"8QN/+0YQPM'0[%B>8^M,)
MVQ'\W&OGP^I:4NQ6LI8BPAHP:W):$@U3`GD0&$Z3'!YO[K>[/DGOFRO1N.N5
M+-&#\:]/+48,SJQY"P.4><\*5WOW]7;168SI9RF4S.V(T]]-+I5:LM_C3'#,
M?AH;9N7"!F4S%O;ZS(,7&BX*`]Q%96ON*'E&OG//A_<^'S$X+.6P4-]=BM-O
M&WF5U@I5B1!BWUK$*"!F1W06GAKQ\NH?>6M>.TZ>Q7</<24POPB(1T"D8T\H
MG3A.=[YS7[4W4NBT&.4IH8QED)@A=??:)EO([2C7;.P)\]>.XNU:#T4[>5HB
MBJYXEZ8&I<EZQ;TQDA471V\HY:\,JX/NNGAJS6]=E?&=S9.FECI&`EI+33""
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M#^=V>_K]7'VO^"F_?.OH?\2/3^/_`"?Z-I]7+AGI?\+.GLG_`-0^;_./Z;YS
M^E;/;^\__]H`"`$!`P$_(8[CRA)?:W.3)`:(*R&G?9?N"%73]]/VGS\_0KMZ
M98FQ7=L*EAKN]T):*S6!-7&TKR81]&ZQ5]]3FI'?UH>TL+!L=48SN;J\JRD*
MQWM*`6$U#B=2WE.ZVN`M,!<0W*M2=/1%4;(6G_DL!RDXX5H6\L&F]RP5[S:^
MWS#<2[(@%3R+K`$HHY`VXJ0R,3JB@%W@4;9,(*OIJ2K!4&6D%3QU*PKY$#:`
MXT$U7E84&DL"P"OR`W<V"T%2`QS@:2D*<DWEC;,V-/![S$4:I4V_F8=6HG1U
M%$.Q0PRUL13,Y\I6S/3+`2TG3HN^$Z<&,-`XQNK)6`LUH;<H=[ITH;?+1NR<
MW&<="RMCWNX6#:9#UU_B[=W*;3K;CU4E(;2QNU/YIT(9#96#$ZVL[H7<;`6>
MB,,JE";C@H<G2./_`"4XWTLOW]4%+TZY()O^`*CJ$H*+;]FU<L2QK/N+&Z;.
M'0BGJ.J\K#0EJKHR\=`R)E!5]$8Y;/%K(Q+U\0(&F6JX@"(O3>ABB9]E86LJ
MQ2%\`(-5)-9J[X,IDA)!\5;C88-&A@CB1K1QDA<HN0M&>^%**[JUN(5-,5AJ
MN<R=Q4C<(J#HY`4E"PBJ3?)<UPPTW))5IFZ2-@F'D?,"7933(O*9N7!-J8N$
M>0]AEJ9>N>QW**BMJ3%H-/PNQ0IK<`BDZ;*.M75YCS4$?!A0M*<J,&:_F8>7
M*8LJ]6DY`BZU"TE$50*=R;S3*K@?C),P(18KP$4$W,=P10."35#R$&+8FS?D
M0T0T@`K(Y.&RD32),)3M@L*-FLIN++`:=D+)JJ%%81.4%L:^!DER\AE'2+`F
MY7VCC%B06HZ+4<K`<P%AE6S%,@QA!Z*?B#N8V.Q2#;G,'/4%ED&"A;N0E#K\
M_?2,L&`^Q@;CLG?_`'FVOQ-&@?#=`ZOC9[UNVB.Q:!6"H`CA:UDPLB-2L'1S
MX<F:G.]*)<!L5]B>1P"7$.=MWMY#]R+&'($,,LL<HD`U3$EJQ4@-AF22#+$7
MH#PU3_2P$?$+66%CE[/`J`)9K9W.I+>UE]-I?55T*%VRHJ&$Y"7;EBR4U7K%
MV)999M#`TEXHV%:H`ERVE*7&$%,!7P]*3*)G-U,49UR0>VXK7C"YW3;2(B@"
M8@!:AH`YFK)F/%;U(PI@3_.B`_/&LD=6FT7.:ECXP?Q(?WTF$#A6#%*0HR=L
MP_V6K0`X+LL2#'R,*:++2V;8#&9L\@45&QCAED1HV!RL>TUC-#Z;&K80,-!S
M<-LQE^D("N1E44DD=1%JYV`7F=.S*L;J'>N)>`,>+^H5%`5&)4TO52EH!+4L
M&(G>%JNS:L%T"9B7W']E0,!%F*ITRZ3PLJ##"%W'0"PF&0546P`;DYNBEW%-
M,M^U4XK1+H8&A#R7-:96(T&IRA+4J$HK0%*(P(I^*VZGVW_V=J':;7VC6_29
M/R;_`/HR\)[M/_:31WLW_7;]E__:``@!`@,!/R&,O^-$`Q;O228H-?M*@K0?
M-0*,%>@P9;?LG"?J.,Q:$&?A,UN[^FE6:FH`"V/8._YEL5\-8X(=-QVM3I&-
MI7)^:C:ZQ'M^GB-JG2?'\RRXM?\`GTDYN-!1;P9_,U)ZT8'!6(86)GAP[-9^
M\PN!0Z:=QN)\I"5@\<GZ>>(DS0_;AE9;U]*%&1$'0O\`Q@WB%H4.-3K\U"*[
M.OF:W_/`B5+_`&'*DM=H#*A\(G4]B1WVV8MZ/>F8DLYUKB"#@^8+^QL"3`[L
M_IZ,LMF7/L3K.M[_`.FLI;S,O#^H=*>*_ONOV3UW/.7]UXGC;G_K.K>/<<Z>
M*FG+^7[+_]H`"`$#`P$_(9RHY!$:H=IGC3^TNQN7\$'US:ZOVYCYV.3E=_4+
MC3U`LB[P]-X\'2">3JW68/CZ1MKF;3.A39J\\=O]EY=NV!SGK&+3XJ7.DSPT
M^(_>6'T*$MPC26FI$VF0F,,H$I(8CX"5KVP?Z9^E@@7"1:.=:W,F]@6W5E[S
M8Z;<?ZBL6MNIYESCK5<FO!*]-HB`E\M(K::H;U$O,LP9)MZ.G_HB=.?HJ+.`
MQW@TEUY]9I;WG_HD*_%QFZL'LS:G5\H]%3!SZ#(P-Q5!?6&_7>9@K]7W(UMW
MY0'YF@LB!ATLOY,0P[:7:V/NWQ`)M".O7G#3S-_36:PW]+O!F?1F%Z@/DA(!
MVU_LA=PT9M8U`X?[^[#$6X-2U]1:0:;BF_2Y:7]/3K[\SQ=??M.[>W_'YG1K
M/M/)?7M/=^R?_]H`#`,!``(1`Q$``!`;D`````````5D"40`T$$`!"%PF66&
M:Z`#6$F2@FR>2`QPM!R`6F043(M^4QB0P9T`22::$R42DB"3;EX``">```#_
MV@`(`0$#`3\0C0A*U6/J*2@(@$-^*EN-U-C+PB2@%==-F:T.EMX?VE*G`!I9
MD!H4A?+`40\`"!!Q2J[2@MVD)[60.71<Y8Z;II\]/,8;VF>7>LQ'-"O-6/D>
MMD+B!'J(+\UY&C6P4@&I[\3!LI,P$VRD,ES*!<9BL(0GOZ2+40+&FX[2("%@
MN:505M05,552_P#^Q&"T[9!ME-*5H!'D1'4+O"M_FL6@B*#,9H*U/1?&Y$#<
M<]0%N4M(MI1<1B;O:(8JC'L_2XB-YHPJ'("J7VAIL\XQW_#RBF5>1CB`3U'H
M%Q(W4\G("`6@:\!K]^L%!8L!88@=8PP*Q0&;3=1<_H\<U7GZ?*V3&(;&2W!I
MIN-:0\8Z`%KF-%/9;A]=N*)`EFP00CTLPC"R;UL=TJ$P/:0,+.V,P@%(ZLJS
M=W,ZOO,BX7E]QA37+U>I]3]KBB=K$.JJG6A-$%8<Z!.W1S/L*@RO*15B0/13
M"JBHM+1="U\'+!JL*[1V%X?6SO:@CT,GPNED?W9J>D'$Y'6!<>N?MB+6]SBI
M#CV^->]6G*#'8HO`HL8;5M4I3!2,X]?3[RE`BD+/:4!/IFS.&60A+8D*"QMX
MB0>0[OZ("_:`AE%[7>:]!5C$HY=CADP[2ZK!\>)-+16CKT-L<79$4R`N,.?-
M2JE+M1DC^4,2J/-O[&V!I5`)ES=[F1YH#($K3+3?P`9CI(5PZT[K7*P01E.(
M6""T'*3Y2+'@.-:"^+(#846B7*315=R'].*P?)J]/QK<U1^8$U@&U%":".0R
M[NMJ!8!@+<!M=!5#'C-<"_F8*#?A0V6;;"#`O#H=JWF:C0R_=5UBF44LH.D>
MEROTC2(5Z"(,`0_&8EG[RP2BM4%_7<-SGA!IU98F01%:Q$1&X*\2JMMJ_,$,
ME@>_&':<(_3@BV]0%?RB+%52)%0+M[>+S"H0%H1`.+1D;I!]HT5I>O0Y.Q,(
ME8%%54=7=<5\ROX)8.BA:=OX4`_9`:F,8\'-`N4VNRTA@*#H]5P"'O,'ID\'
M14I/LY]CB+ON?$Y:A4TS;O$>;R'A<TZTQ1R0.QS*JE+1(CF&U`0I_)?HU5:Z
MD5:@Z<5MRR`HB%*[#/0.F@J2VJ/7"A+W-6B:.6D1Y$#7+J1*K;=7;Q<?2PER
MZR9<O-N_$EL("N4"!8@(A8B,6./S[IKU%F#8HEW4N5>(`CWJ6<].S2(L!%!Q
M<8!2(DIAFV@QI*(MLZA3A*B+NO6.9T,SI.*]Z-CB'*QAQSD1'(9GK8GN6(,T
M;4&5C_R@NT7;2JJ4OW`^S\?Q!QA:U`(&PHRP(3VBH%>K]:`BA<44`J5P!+2!
M!N.',F8;%3W"U<KMXD,=I5<"1H+N95MQ=\(HF`_Q;JY0OD#@'`F"W)+$O\C`
M`T5%(P?E6<(?['\YJE*<!D,+ZOPJ&\L&48J4Q0FGF:\K3/+=P'E_*G57#A/&
M"_00V5!J2H3LK0EQC+!I:$MPEIBF<(>ZP@'&(QRN$/)'1<H=3TT<O<!,YDC3
MPE&C.I%A!S"LZ.])@R>>#E91SN`#@:ECZP=A_P"(W,6Z7QEKO'?;^TH7'ZJG
MW;1WK?G<3_8""OL3<_T;]NCM#1X/K=/CT-'C]#__V@`(`0(#`3\0F.P:](&X
M>*O#"ZI*:"U=]3%G$JX8:_:)+%B<(J_O@J&5'1AX,[IU6DPQ0KM8Y1U`F1^0
M?TK)9$HPRI]]?F!`@(&!UEZ5S^9@D"6,:\Y^FU-9:4%I^/XF9J*@UJ[$I0(`
MYR2X]QD.&P075J;,"#B$^7UM!&P**&'K5<7Y"N$>72G8Z2DPPR7Z8XAGZ0ZR
MHV;9Q=<M:KC?>"?-8PLZFEJRWQ7%0E%\\)?+5#@SH'O]+1][$;/4#6G!7,5E
MB)J)KI0.*8D:&E4MI4G3!9AJ"(:P466QPLL=(D([6E3<:`H9+5H3DAT/4.8_
M1<O$4&`_S\QZW3RV\V1C=>TT`)TF+^<_/TDVSKV*#X)8Y:F%"C+IG)SS`;Q5
M3UZQJ`+/0JNUU[J_$P@<QY"6>]PNZ#N@KX"(BZUZ#Z8]0N5Z,X]67'4^:,2)
MVPGM+Y$E=KW6=E#WU&P"Y01.$:3WJ/MP*J,:CD'9K`%YB>BOF,-@[M!#&:*Z
M87\^I^@[G'TE%JB"\L!LHX,/F)($5WIDQ2/<[L=\R*EZ6<[E<8J-"58&$U>-
MF@QMEJ;0V&QP(H4%T+08CO\`0I_1MT%>WXS*V^0]'M>,74P^,ZFN/^O7,]R[
ML7D^Y=7B7X7/'ESMYOVA=%W???O6/C]C_]H`"`$#`P$_$(I.M<-+E<WS!+4K
M.:7C=.:^V"BHZGM^T:M0!7)^!F6^BY:=S)D/+WA3SVPP+2G1QZUKC&_43J97
M<6"T(KBOOV]!]`Z>9Q2Z2SL\NB)3"'5SX^EGK5;!3)VS_-0\J",F!9IM>2<"
M0-QR)2T:)L5QT4S$>-%`HA$`*C>CCB!*$*B4EU1;?7&_3`&[C_H1-J@Q>("J
MH$&!W4-#O$LIXC('3'$@S#P9!N521""+M#C`4_C<U^*1WQ9NTJ[-_26B$P6$
M<G!8:)"MI'<VEKPGRP1<RG)&"10[EU6(Y9%F;7%'`A5\[(3"-0652U$7+KXE
MC'H;E#7!"%,XU?O&J$0,ZN,QZ(`/5!!0''>9R*I8,.NV3/1(H&%.11KXQ\<^
MH+J6BM<4<!97WA4!$Y#)MWQCV@481*'3I\0%W>3"4[EL.M:B#K\.'9[5?XC`
MVH=4%]VWWCN9!U4P4]":'$8`S7YBTJIRJ3XE%$U4U>\-OLOKDAU4]FZCE*(\
M#$W\C!LGMM&@O;->+E?4X0HG6\F(B?+4EQ>MT-#5VQ0PX[Y3X+596@NO+'\0
MAAT@5HW,7X]3MS1_,SDT>/14V?R_Y'3OE?I5PN)4*\*FQQ9[\0V!5BTZ9JAV
M8/%X@0%BL;>&V/![RBT@RB-YMO%[<;XE;6TPU?EFJ-#?7<%._P#<16[B*S<=
MSUNK[CCT,[RC5XU!!1J`ZEOS].[O>8O_``;\?ZLSSFUHWF^;_C%SNF]U?<#*
0-XU7BZKVV^?T#?H[_0__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
